Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction

Chinese medical journal pulmonary and critical care medicine Pub Date : 2024-06-01 DOI:10.1016/j.pccm.2024.04.003

Zhen Zheng, Fei Peng, Yong Zhou

{"title":"Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction","authors":"Zhen Zheng, Fei Peng, Yong Zhou","doi":"10.1016/j.pccm.2024.04.003","DOIUrl":null,"url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a dismal prognosis. Early diagnosis, accurate prognosis, and personalized therapeutic interventions are essential for improving patient outcomes. Biomarkers, as measurable indicators of biological processes or disease states, hold significant promise in IPF management. In recent years, there has been a growing interest in identifying and validating biomarkers for IPF, encompassing various molecular, imaging, and clinical approaches. This review provides an in-depth examination of the current landscape of IPF biomarker research, highlighting their potential applications in disease diagnosis, prognosis, and treatment response. Additionally, the challenges and future perspectives of biomarker integration into clinical practice for precision medicine in IPF are discussed.</p></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 2","pages":"Pages 72-79"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772558824000240/pdfft?md5=381b53fe7d1a86f6287eea01a6e1c1aa&pid=1-s2.0-S2772558824000240-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese medical journal pulmonary and critical care medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772558824000240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a dismal prognosis. Early diagnosis, accurate prognosis, and personalized therapeutic interventions are essential for improving patient outcomes. Biomarkers, as measurable indicators of biological processes or disease states, hold significant promise in IPF management. In recent years, there has been a growing interest in identifying and validating biomarkers for IPF, encompassing various molecular, imaging, and clinical approaches. This review provides an in-depth examination of the current landscape of IPF biomarker research, highlighting their potential applications in disease diagnosis, prognosis, and treatment response. Additionally, the challenges and future perspectives of biomarker integration into clinical practice for precision medicine in IPF are discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

特发性肺纤维化的生物标志物：当前洞察力和未来方向

特发性肺纤维化（IPF）是一种慢性进行性间质性肺病，预后不佳。早期诊断、准确预后和个性化治疗干预对改善患者预后至关重要。生物标志物作为生物过程或疾病状态的可测量指标，在 IPF 的治疗中大有可为。近年来，人们对鉴定和验证 IPF 生物标志物的兴趣与日俱增，其中包括各种分子、成像和临床方法。本综述深入探讨了 IPF 生物标志物研究的现状，重点介绍了它们在疾病诊断、预后和治疗反应中的潜在应用。此外，还讨论了将生物标记物融入临床实践以实现 IPF 精准医疗所面临的挑战和未来展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chinese medical journal pulmonary and critical care medicine Critical Care and Intensive Care Medicine, Infectious Diseases, Pulmonary and Respiratory Medicine

CiteScore

0.40

自引率

0.00%

发文量

期刊最新文献

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment Patterns and trends in asthma incidence rates in main Asian and Western countries and their prediction to 2030 Screening for viruses in lung adenocarcinoma in China Guide for Authors Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development